Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel George

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Resilience and vulnerabilities of tumor cells under purine shortage stressJianpeng Yu, Chen Jin, Cheng Su, et al.
Cancer Medicine|September 4, 2021
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinomaLisa P Spees, Stephanie B Wheeler, Bradford E Jackson, et al.
Journal of Geriatric Oncology|February 7, 2022
Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinomaDeborah R Kaye, Lauren E Wilson, Melissa A Greiner, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 22, 2024
Differences in Serum miRNA Profiles by Race, Ethnicity, and Socioeconomic Status: Implications for Developing an Equitable Ovarian Cancer Screening TestStephanie Alimena, Briana Joy K Stephenson, James W Webber, et al.
British Journal of Cancer|September 11, 2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinomaThomas Powles, Robert J Motzer, Bernard Escudier, et al.
JCO Oncology Practice|November 22, 2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer TherapyHannah E Dzimitrowicz, Lauren E Wilson, Bradford E Jackson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2023
Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European StudyFilippo Biscarini, Giulia Masetti, Ilaria Muller, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Resilience and vulnerabilities of tumor cells under purine shortage stressJianpeng Yu, Chen Jin, Cheng Su, et al.
Cancer Medicine|September 4, 2021
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinomaLisa P Spees, Stephanie B Wheeler, Bradford E Jackson, et al.
Journal of Geriatric Oncology|February 7, 2022
Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinomaDeborah R Kaye, Lauren E Wilson, Melissa A Greiner, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 22, 2024
Differences in Serum miRNA Profiles by Race, Ethnicity, and Socioeconomic Status: Implications for Developing an Equitable Ovarian Cancer Screening TestStephanie Alimena, Briana Joy K Stephenson, James W Webber, et al.
British Journal of Cancer|September 11, 2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinomaThomas Powles, Robert J Motzer, Bernard Escudier, et al.
JCO Oncology Practice|November 22, 2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer TherapyHannah E Dzimitrowicz, Lauren E Wilson, Bradford E Jackson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2023
Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European StudyFilippo Biscarini, Giulia Masetti, Ilaria Muller, et al.
Pageof 16